173 related articles for article (PubMed ID: 17534387)
1. Targeted therapies: the answer to individualized treatment?
Hutchinson L
Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387
[No Abstract] [Full Text] [Related]
2. Targeted therapy and pharmacogenomic programs.
Iqbal S; Lenz HJ
Cancer; 2003 Apr; 97(8 Suppl):2076-82. PubMed ID: 12673699
[TBL] [Abstract][Full Text] [Related]
3. Are targeted therapies really targeted?
Schilsky RL
Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
[No Abstract] [Full Text] [Related]
4. Rational targeting of Notch signaling in cancer.
Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
[TBL] [Abstract][Full Text] [Related]
5. Bundling next-generation cancer therapies for synergy.
Kling J
Nat Biotechnol; 2006 Aug; 24(8):871-2. PubMed ID: 16900109
[No Abstract] [Full Text] [Related]
6. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
7. MAPKs: function, regulation, role in cancer and therapeutic targeting.
Dhanasekaran DN; Johnson GL
Oncogene; 2007 May; 26(22):3097-9. PubMed ID: 17496908
[No Abstract] [Full Text] [Related]
8. Clinical cancer research 2001: new agents and therapies.
Verweij J; de Vries EG
Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676
[No Abstract] [Full Text] [Related]
9. New skin cancer target could delay drug resistance.
Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687783
[No Abstract] [Full Text] [Related]
10. Minicells mitigate tumor growth.
Dorans K
Lab Anim (NY); 2009 Aug; 38(8):250. PubMed ID: 19626008
[No Abstract] [Full Text] [Related]
11. Molecular-targeted therapies: lessons from years of clinical development.
Rosa DD; Ismael G; Lago LD; Awada A
Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
[TBL] [Abstract][Full Text] [Related]
12. Cancer-BIT Life Sciences' second world congress. 22-25 June 2009, Beijing, China.
McKeown S
IDrugs; 2009 Sep; 12(9):543-6. PubMed ID: 19697270
[No Abstract] [Full Text] [Related]
13. Introduction to resistance to anticancer agents.
Kruh GD
Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
[No Abstract] [Full Text] [Related]
14. [The pathologist and targeted therapies in oncology].
Bertheau P
Ann Pathol; 2009 Nov; 29 Spec No 1():S69-70. PubMed ID: 19887258
[No Abstract] [Full Text] [Related]
15. Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
[No Abstract] [Full Text] [Related]
16. Nanoparticles for delivery of chemotherapeutic agents to tumors.
Vijayaraghavalu S; Raghavan D; Labhasetwar V
Curr Opin Investig Drugs; 2007 Jun; 8(6):477-84. PubMed ID: 17621878
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies: aiming for the bull's-eye.
Gaguski ME
ONS Connect; 2007 Jul; 22(7):8-12. PubMed ID: 17694778
[No Abstract] [Full Text] [Related]
19. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
20. CD70 as a therapeutic target in human malignancies.
Grewal IS
Expert Opin Ther Targets; 2008 Mar; 12(3):341-51. PubMed ID: 18269343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
